Convergent mutation trajectories convert functional self-tolerance in IGHV4-34 B cells to genetic tolerance encoded in the antibody
Preventing autoantibody secretion by rendering self-reactive B cells functionally silent through clonal anergy has long posed the question of why fill the circulating B cell repertoire with cells that cannot secrete antibody? Here we address this question from the perspective of B cells that comprise 5 to 10% of the human circulating repertoire, expressing self-reactive surface immunoglobulins employing the IGHV4-34 heavy chain variable element. Using gene targeting to construct mice expressing a representative human IGHV4-34 antibody on the surface of many B cells, we show these cells are prevented from autoantibody secretion by B cell clonal anergy marked by downregulation of surface IgM, induction of tolerance-response mRNAs, and exclusion from the marginal zone and B1 cell subsets. This functionally tolerant state is overridden when the IGHV4-34 B cells cross-react with a virus, which stimulates the self-reactive B cells to hypermutate in germinal centers. Within 16 d of infection, 99% of daughter cells have acquired one of five heavy chain mutations that diminish binding to self but preserve virus binding, and 33% had combined 2 or 3 of these mutations to make their antibodies genetically self-tolerant and virus specific. These results demonstrate, from the perspective of a pathologically important human autoantibody class and the world's most successful virus vaccine, how human antibody specificity is sculpted in the progeny of anergic B cells to yield antibodies that bind a virus but not self.
Authors
- Megan Faulks
- Joanne H. Reed (ORCID: https://orcid.org/0000-0002-7585-7848)
- Christopher J. Jara
- Stewart A. Smith (ORCID: https://orcid.org/0000-0001-5806-7361)
- David C. Tscharke (ORCID: https://orcid.org/0000-0001-6825-9172)
- Timothy J. Peters (ORCID: https://orcid.org/0000-0003-3690-5293)
- Deborah Lilly Burnett (ORCID: https://orcid.org/0000-0002-5642-3315)
- Eric Chen Quin Lam (ORCID: https://orcid.org/0000-0002-2270-926X)
- Robert Brink (ORCID: https://orcid.org/0000-0002-9586-3655)
- Katherine Jackson (ORCID: https://orcid.org/0000-0002-9952-7069)
- Christopher C. Goodnow (ORCID: https://orcid.org/0000-0001-5296-6155)
- Lisa A. Miosge (ORCID: https://orcid.org/0000-0001-8317-3377)
- Etienne Masle‐Farquhar (ORCID: https://orcid.org/0000-0001-9355-8027)
- Amanda Russell
- Sherin Zachariah
Institutions
- Australian National University (AU)
- The University of Sydney (AU)
- Garvan Institute of Medical Research (AU)
- UNSW Sydney (AU)
- Futures Group (United States) (US)
- St Vincent's Clinic (AU)
- Westmead Institute for Medical Research (AU)
Publication Details
- Journal
- Proceedings of the National Academy of Sciences
- Published
- 2025-12-18
- DOI
- https://doi.org/10.1073/pnas.2522257122
- Citations
- 1
- Primary Topic
- T-cell and B-cell Immunology
- Type
- article
- Field-Weighted Citation Impact
- 0.80
Funders
- Rebecca L. Cooper Medical Research Foundation
- University of New South Wales
- Medical Research Council
- National Health and Medical Research Council